Biogen Idec and Neurimmune Therapeutics entered into a global development and marketing agreement for Alzheimer's disease treatments. The collaboration will focus on developing fully human antibodies that bind to the amyloid beta molecule, the companies specified Tuesday.
As part of the deal, Neurimmune will be responsible for identifying potential therapeutic antibodies, and Biogen Idec will be responsible for developing and marketing all resulting products. Biogen Idec could pay Neurimmune as much as $380 million in upfront and milestone payments, plus royalties on sales of any marketed drugs developed as part of the collaboration.
To read more Top Story articles, click here.